Hill Joshua A, HallSedlak Ruth, Magaret Amalia, Huang Meei-Li, Zerr Danielle M, Jerome Keith R, Boeckh Michael
Department of Medicine, University of Washington, United States; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, United States.
Department of Laboratory Medicine, University of Washington, United States.
J Clin Virol. 2016 Apr;77:71-6. doi: 10.1016/j.jcv.2016.02.016. Epub 2016 Feb 20.
Human herpesvirus 6 (HHV-6) has a unique ability to integrate into chromosomal telomeres. Vertical transmission via germ cell integration results in offspring with inherited chromosomally integrated (ci)HHV-6 in all nucleated cells, affecting ∼1% of the population.
Inherited ciHHV-6 may be a direct or indirect mediator of human disease, but efficient identification of affected individuals is a fundamental roadblock to larger studies exploring the clinical importance of this condition.
A group testing strategy was designed to efficiently identify individuals with inherited ciHHV-6. DNA was extracted from 2496 cellular samples from hematopoietic cell transplant (HCT) donor-recipient pairs. Pools of 12 samples were screened for HHV-6 DNA with quantitative (q)PCR. Individual samples from high positive pools were tested with qPCR, and high positive individual samples were tested for inherited ciHHV-6 using droplet digital (dd)PCR to determine HHV-6 DNA copies/cellular genome.
Thirty-one pools had high positive HHV-6 DNA detection with >10(3) HHV-6 DNA copies/μg. Each pool had one sample with >10(4) copies/μg HHV-6 DNA. Inherited ciHHV-6 was confirmed by ddPCR in every high positive sample (>10(3) HHV-6 DNA copies/μg), yielding a prevalence of 1.5% in HCT recipients and 0.96% in donors. We performed 580 qPCR tests to screen 2496 samples for inherited ciHHV-6, a 77% reduction in testing.
Inherited ciHHV-6 can be efficiently identified by specimen pooling coupled with modern molecular techniques. This algorithm can be used to facilitate cost-effective identification of patients with inherited ciHHV-6, thereby removing a major hurdle for large-scale study of its clinical impact.
人类疱疹病毒6型(HHV-6)具有独特的整合到染色体端粒的能力。通过生殖细胞整合进行垂直传播会导致后代所有有核细胞中都存在遗传性染色体整合(ci)HHV-6,影响约1%的人群。
遗传性ciHHV-6可能是人类疾病的直接或间接介导因素,但有效识别受影响个体是探索这种情况临床重要性的大型研究的一个基本障碍。
设计了一种分组检测策略,以有效识别患有遗传性ciHHV-6的个体。从造血细胞移植(HCT)供体-受体对的2496份细胞样本中提取DNA。用定量(q)PCR对12个样本的混合样本进行HHV-6 DNA筛查。对高阳性混合样本中的单个样本进行qPCR检测,对高阳性单个样本使用液滴数字(dd)PCR检测遗传性ciHHV-6,以确定HHV-6 DNA拷贝数/细胞基因组。
31个混合样本的HHV-6 DNA检测呈高阳性,HHV-6 DNA拷贝数>10³/μg。每个混合样本都有一个样本的HHV-6 DNA拷贝数>10⁴/μg。通过ddPCR在每个高阳性样本(>10³ HHV-6 DNA拷贝数/μg)中确认了遗传性ciHHV-6,在HCT受者中的患病率为1.5%,在供体中的患病率为0.96%。我们进行了580次qPCR检测,以筛查2496份样本中的遗传性ciHHV-6,检测次数减少了77%。
通过样本合并结合现代分子技术可以有效识别遗传性ciHHV-6。该算法可用于促进对遗传性ciHHV-6患者的经济高效识别,从而消除对其临床影响进行大规模研究的一个主要障碍。